Motor Neurone Disease Trial, Recruiting NCT03233646 Sponsor: Duke University Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT03233646
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults who have been diagnosed with a neurodegenerative condition, such as mild cognitive impairment (MCI), Parkinson's disease, Alzheimer's disease, ALS, multiple sclerosis, Huntington's disease, traumatic brain injury, concussion, PTSD, Down Syndrome, or similar conditions
  • Adults who do not have a neurodegenerative condition (healthy volunteers may also be eligible)

Who may not be able to join:

  • People who are unable to cooperate with or complete the testing, or who have eye or vision conditions related to age or other neurological causes that could affect the quality of eye images taken during the study
  • People who have had eye surgery inside the eye itself, except for cataract surgery (having had cataract surgery is acceptable)

A note about eye eligibility:

  • If both of your eyes meet the study requirements, both may be included; if only one eye qualifies, just that eye will be included in the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sharon Fekrat, MD FACS FASRS, Duke University

Phone: 919-681-3937

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
20 July 2017
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in ganglion cell-inner plexiform layer (GCIPL) thickness; Change in retinal nerve fiber layer (RNFL) thickness; Change in central subfield thickness (CST); Change in choroidal vascularity index (CVI); Change in foveal avascular zone (FAZ) area; Change in average perfusion density (PD); Change in average vessel density (VD); Change in average capillary perfusion density (CPD); Change in average capillary flux index (CFI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov